Pharming Group N.V. signed a research collaboration with NovaThera Limited. Pharming and NovaThera are to collaborate on combining NovaThera’s proprietary biomaterial products with Pharming’s recombinant proteins such as human collagen, fibrinogen, lactoferrin and C1 inhibitor. The collaboration takes advantage of the complementary capabilities of products from Pharming and Novathera and could provide Pharming with several new products.

NovaThera was founded to commercialize pioneering technologies emanating from the Tissue Engineering and Regenerative Medicine Department of Imperial College London, a world-class research centre combining biology, biomaterials and bio-photonics expertise.

“NovaThera’s research capabilities in the fields of tissue engineering and regenerative medicine provide an exciting opportunity for Pharming,” Dr. Francis Pinto, CEO of Pharming said adding, “Pharming will further strengthen its pipeline with new products and build on the value of its proprietary recombinant proteins.”

Pharming retains commercial rights to the new products and ownership of the intellectual property developed in the collaboration. NovaThera will receive milestone payments and royalties linked to successful development of new products.

Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company’s products include potential treatments for genetic disorders, specialty products for surgical indications, and intermediates for various applications.